Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norgestimate + ethinyl estradiol + folic acid is a combination oral contraceptive containing two synthetic hormones—norgestimate (a progestin) and ethinyl estradiol (an estrogen)—along with folic acid, a B-vitamin. The primary indication is the prevention of pregnancy. The contraceptive effect is achieved by inhibiting ovulation, altering cervical mucus to impede sperm penetration, and modifying the endometrial lining to reduce the likelihood of implantation. Norgestimate acts as a prodrug that is metabolized into active metabolites after oral administration. Ethinyl estradiol increases sex hormone-binding globulin levels and both components are extensively protein-bound in plasma[1][2][5]. Folic acid supplementation in these formulations aims to reduce the risk of neural tube defects should conception occur shortly after discontinuation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norgestimate + ethinyl estradiol + folic acid.